Could a common muscle drug and vitamin e heal jaw bone death?

NCT ID NCT03040778

First seen May 07, 2026 · Last updated Jun 22, 2026 · Updated 8 times

Summary

This phase 3 trial tests whether a combination of pentoxifylline (a muscle pain drug) and vitamin E can help heal jaw bone damage caused by osteoporosis or cancer treatments. About 100 people with medication-related jaw bone death will receive either the drug combo plus standard care, or standard care alone. The main goal is to see if the exposed bone area shrinks after one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDICATION-RELATED OSTEONECROSIS OF THE JAW are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • New York Center for Orthognathic and Maxillofacial Surgery

    Lake Success, New York, 11042, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35242, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109-0018, United States

  • University of Washington

    Seattle, Washington, 98195, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Pentoxifylline and Vitamin E (tocopherol)

What this could lead to

If it works, this drug combination could become a non-surgical treatment to heal jaw bone damage caused by osteoporosis or cancer medications.

What could go wrong

This is a mid-stage trial with only 100 participants, so results may not apply to everyone. The drugs may not shrink the bone exposure better than standard care alone.

Conditions

The condition(s) this trial relates to.

Bisphosphonate-Associated Osteonecrosis of the Jaw osteonecrosis osteonecrosis of the jaw

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.